高瀾股份(300499.SZ):擬4.09億元轉讓東莞硅翔31%股權 將獲投資收益3.82億元
格隆匯11月7日丨高瀾股份(300499.SZ)公佈,公司持有東莞硅翔51%的股權,擬按照東莞硅翔整體估值13.20億元向深創投製造業轉型升級新材料基金(有限合夥)等各方投資機構轉讓31%的股權,轉讓價款約4.09億元;同時,深創投製造業轉型升級新材料基金(有限合夥)擬按照增資前估值14.00億元出資1.50億元對東莞硅翔進行增資。
該次股權轉讓暨增資完成後,公司將繼續持有東莞硅翔18.0645%的股權,東莞硅翔不再為公司控股子公司,將不再納入公司合併報表範圍。經公司財務中心初步測算,該次股權轉讓預計為公司帶來投資收益3.82億元,最終數額以審計機構審計結果為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.